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A marked proliferation of synovial ﬁbroblasts in joints leads to pannus formation in rheumatoid arthritis (RA). Various kinds
of cytokines are produced in the pannus. The purpose of this study is to elucidate the eﬀects of phosphodiesterase 4 (PDE4)
inhibitors in a new animal model for the evaluation of pannus formation and cytokine production in the pannus. Mice sensitized
with methylated bovine serum albumin (mBSA) were challenged by subcutaneous implantation of a membrane ﬁlter soaked in
mBSA solution in the back of the mice. Drugs were orally administered for 10 days. The granuloma formed around the ﬁlter was
collected on day 11. It was chopped into pieces and cultured in vitro for 24 hr. The cytokines were measured in the supernatants.
The type of cytokines produced in the granuloma was quite similar to those produced in pannus in RA. Both PDE4 inhibitors,
KF66490 and SB207499, suppressed the production of IL-1β,T N F - α, and IL-12, and the increase in myeloperoxidase activity, a
markerenzymeforneutrophilsandhydroxyprolinecontent.Comparedtoleﬂunomide,PDE4inhibitorsmorestronglysuppressed
IL-12 production and the increase in myeloperoxidase activity. PDE4 inhibitors also inhibited lipopolysaccharide-induced TNF-α
and IL-12 production from thioglycolate-induced murine peritoneal macrophages and the proliferation of rat synovial ﬁbroblasts.
These results indicate this model makes it easy to evaluate the eﬀect of drugs on various cytokine productions in a granuloma
without any puriﬁcation step and may be a relevant model for evaluating novel antirheumatic drugs on pannus formation in RA.
PDE4 inhibitors could have therapeutic eﬀects on pannus formation in RA by inhibition of cytokine production by macrophages
and synovial ﬁbroblast proliferation.
Copyright © 2007 Katsuya Kobayashi et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1. INTRODUCTION
Rheumatoid arthritis (RA) is a systemic autoimmune dis-
ease characterized by the progressive chronic inﬂammation
of multiple joints. The incidence of RA is close to 1% world-
wide, but its etiology is not yet known. The search for
therapeutic agents for RA is being conducted mainly us-
ing collagen-induced arthritis and adjuvant-induced arthri-
tis [1, 2]. In the development of arthritis, pannus for-
mation is the critical step in the destruction of carti-
lage and bones. Pannus is a proliferative granulomatous
tissue, mainly composed of macrophages and ﬁbroblast-
like synoviocytes. Pannus contains numerous cytokines and
proteases inside. Although collagen-induced arthritis and
adjuvant-induced arthritis models are very useful for screen-
ing candidates for novel antirheumatic drugs, it is not easy
to elucidate the eﬀects of candidates on the pannus for-
mation. Also, quantitative analysis of cytokine levels is re-
quired to elucidate the role of cytokines in the pathogene-
sis of pannus formation. However, many steps are needed
to measure cytokines in the pannus in arthritis models.
For example, the ankle joints have to be removed, frozen
in liquid nitrogen, crushed, homogenated, and ﬁnally cy-
tokines are assayed by enzyme-linked immunosorbent as-
say (ELISA) in the supernatants [3]. Therefore, an inﬂam-
matory model is needed to simply evaluate the eﬀects of
drugs on pannus formation and cytokine production in pan-
nus.
There is only a few animal models available for the eval-
uation of antiarthritic drugs on pannus formation. One of
the granuloma models, a cotton pellet-induced granuloma
model, is widely used as a model for pannus formation [4].2 Mediators of Inﬂammation
The problem with this model is, however, that the granu-
loma is formed by a foreign-body-dependent granuloma re-
action. The mechanism of pannus formation has not been
fully proven yet, but T cells seem to be involved in pannus
formation [5]. Another granuloma model, delayed-type hy-
persensitivity (DTH) granuloma, has been reported to be
antigen-speciﬁc and T cell-mediated [6–8]. Histological fea-
tures of the lesions from DTH granuloma revealed the evo-
lution of DTH into a chronic glaucomatous reaction, as
shown by the following changes: ﬁbrin deposition, vasculitis,
mononuclear cell inﬁltration/proliferation, and angiogenesis
[6]. They reported that DTH granuloma represented a rel-
evant model for probing pathogenic mechanisms and po-
tential therapeutics for RA. In this study, we modiﬁed the
DTH granuloma model so that we could easily measure cy-
tokine production from the granulomatous tissue. The gran-
uloma was induced by a subcutaneous implantation of a
thin membrane ﬁlter soaked in methylated bovine serum
albumin (mBSA) solution into the back of the mice pre-
viously sensitized with mBSA. For cytokine determination,
the granuloma was collected from the back of the mice on
the indicated days and incubated in culture medium for 24
hours in vitro, and the cytokines were measured in the su-
pernatants.
Phosphodiesterase 4 (PDE4) inhibitors are key enzymes
that degrade cAMP and play an important role in in-
ﬂammatory and immune reactions [9]. The prevention of
cAMP degradation by PDE4 inhibitors elevates the level
of cAMP in the cells followed by suppression of inﬂam-
mation and immune responses. Rolipram is a well-known
PDE4 inhibitor that reduces the inﬂammatory responses
in several rodent models, including carrageenan-induced
edema [10], adjuvant arthritis [10, 11], antigen-induced air-
way inﬂammation [12, 13], lipopolysaccharide- (LPS-) in-
duced lung inﬂammation [14] and collagen-induced arthri-
tis [15]. Inhibitions of leukotriene B4 (LTB4), interferon-
γ (IFN-γ), tumor necrosis factor-α (TNF-α), interleukin-
4 (IL-4), and IL-5 are all potential mechanisms by which
the anti-inﬂammatory eﬀects of rolipram are mediated [16].
These results suggest that PDE4 inhibitors may be thera-
peutic agents for various diseases such as asthma, chronic
obstructive pulmonary disease, and rheumatoid arthritis.
In this study, we evaluated PDE4 inhibitors, KF66490 and
SB207499 [17], in the mouse pannus model and com-
pared the eﬀects of the PDE4 inhibitors with those of typ-
ical antirheumatic drugs leﬂunomide, prednisolone, and
methotrexate.
2. MATERIAL AND METHODS
2.1. Animals
Male,6-week-old BALB/cmicewerepurchasedfromCharles
RiverJapan(Kanagawa,Japan)andmaintainedatatempera-
ture of 22±3◦C and a humidity of 50±20%. Food and water
were provided ad libitum. The study protocol for the animal
experiment was approved by the Animal Care Committee of
Kyowa Hakko Kogyo Co., Ltd.
2.2. Reagents
Leﬂunomide, KF66490 and SB207499 were synthesized in
our institute. Methotrexate (MTX) was purchased from Led-
erle Japan, Ltd. (Tokyo, Japan). Prednisolone, diclofenac
sodium and methylated bovine serum albumin (mBSA)
were purchased from Sigma-Aldrich Japan (Tokyo, Japan).
Sources of other chemicals were as follows: Freund’s com-
plete adjuvant (Difco, Detroit, Mich, USA); myeloperoxidase
(Sigma-Aldrich Japan), hexadecyltrimethylammonium bro-
mide (Sigma-Aldrich Japan); ELISA kits for each mouse cy-
tokine: IL-6 and IL-1β (BioSource International, Camarillo,
Calif,USA),TNF-α(R&DSystems,Minneapolis,MN,USA),
IFN-γ (PIERCE, Rockford, Ill, USA), IL-4 (BD Bioscience,
San Diego, Calif, USA), IL-10 (BD Bioscience), IL-12 (Gen-
zyme, Cambridge, Mass, USA); RPMI 1640 tissue culture
medium(Sigma-Aldrich);fetalbovineserum(Intergen,Pur-
chase, NY, USA); penicillin-streptomycin (Life Technologies,
Rockville, Md, USA); and 2-mercaptoethanol (Wako Pure
Chemical).
2.3. Inductionofgranuloma
Granuloma was induced according to Dunn et al. [6]w i t h
a slight modiﬁcation. Methylated BSA (mBSA: 4mg/mL
in saline) was emulsiﬁed in an equal volume of Freund’s
complete adjuvant. The emulsion (0.1mL containing 200μg
mBSA) was injected intradermally on the back of the mice.
Sevendayslater,thesametreatmentwasrepeated.Twoweeks
after the last sensitization, a membrane ﬁlter (13mm diame-
ter, 0.05mm thickness, Millipore Japan, Tokyo, Japan) which
had been soaked in mBSA solution (4mg/ml in saline) for
60 minutes was subcutaneously implanted in the dorsum of
the mice (day 0). The wound was closed with 9mm autoclips
(Clay Adams, Parsippany, NJ).
2.4. Measurementofcytokinesandanti-mBSA
antibodiesintheculturesupernatants
Mice were killed by CO2 asphyxiation. The granuloma
formed around the ﬁlter was collected from the back of the
mice and chopped into pieces in 4mL of 1640 tissue cul-
ture medium supplemented with 10% heat-inactivated fetal
bovine serum (FBS), 50unit/mL penicillin-50μg/mL strep-
tomycin, and 50μmol/L 2-mercaptoethanol. The tissue was
cultured for 24 hours at 37◦C. Cytokines were measured by
ELISA kits in the supernatants. Anti-mBSA speciﬁc IgG1 and
IgM antibodies in the supernatants were measured by ELISA
[18], and the results were expressed as the absorbance at
450nm.
2.5. Measurementofmyeloperoxidaseactivityand
hydroxyprolinecontentinthegranuloma
Myeloperoxidase activity was measured using a speciﬁc sub-
strate in the mixture of the culture medium and the granu-
lomatous tissue. Brieﬂy, the chopped tissues and the remain-
ing supernatants (total 3.2mL) were mixed with 0.16mL of
potassium phosphate buﬀer (0.5mol/L, pH 6.0) and 0.16mLKatsuya Kobayashi et al. 3
hexadecyltrimethylammonium bromide solution (10%) and
vigorously vortexed. Samples were incubated for 20 minutes
at4◦C.Aftercentrifugation(1800g,20minutes),theenzyme
activity in the supernatant was measured [19]. The remain-
ing tissue and the supernatant were mixed with an equal
amount (3.3mL) of HCl (12mol/L) and incubated for 15
hours at 110◦C for the measurement of hydroxyproline con-
tent according to the procedure of Jakubzick [20]. Data were
expressed as total enzyme activity or total hydroxyproline
content in the granuloma.
2.6. Timecourseanalysisofthemurinepannusmodel
The granuloma was collected on days 1, 3, 6, 10, 15, 22, and
30 and cultured in vitro. A saline-soaked ﬁlter was implanted
in the back of the mice as a negative control group (Saline
group).
2.7. Evaluationofantirheumaticdrugs
andPDE4inhibitors
Alldrugsweresuspendedin0.5%methylcelluloseindistilled
water and orally administered once a day from day 0 to 10.
Control group was treated with 0.5% methylcellulose (Vehi-
cle group). The granuloma was collected on day 11.
2.8. Thioglycolate-elicitedperitonealmacrophages
Male BALB/c mice (8–10 weeks old) were injected intraperi-
toneally with 1ml of 3% (w/vol) thioglycolate broth (Wako
Pure Chemical). Four days later, cells were harvested by
peritoneal lavage with RPMI 1640 medium. The cells were
washed twice, and 2.5 × 104 peritoneal cells (for TNF-α pro-
duction)or2×105 peritonealcells(forIL-12production)per
0.2mL in the same medium containing 10% FBS were then
added to each well of 96-well plates. The cells were allowed
to adhere to well at 37◦C in a humidiﬁed 5% CO2 atmo-
sphere, and after 2 hours, nonadherent cells were removed
by gentle washing. Adherent cells were used as thioglycolate-
elicited peritoneal macrophages. Adherent cells were stimu-
lated with 1μg/mL of LPS for 6.5 hours (for TNF-α)o r2 4
hours (for IL-12) at 37◦C. After the incubation, the super-
natant was collected. Cytokines were measured by ELISA kits
in the supernatants.
2.9. Cultureofratsynovialﬁbroblasts
Surface parts of synovial tissues were isolated from knee
jointsoffemale,8-week-oldLewisrats(CharlesRiverJapan),
followed by washing with phosphate-buﬀered saline (PBS)
and subsequent digestion with 0.2% collagenase in RPMI
1640 medium at 37◦C for 2 hours. Synovial tissues were then
treated with 0.2% collagenase and 0.25% trypsin at 37◦C
for 2 hours. Cells were collected in RPMI 1640 containing
10% FBS and antibiotics, and then centrifuged at 500xg for
5 minutes. The pellets were suspended in RPMI 1640 con-
taining 10% FBS. Cells were used for experiments after three
to eight passages as synovial ﬁbroblasts.
2.10. Proliferationofratsynovialﬁbroblasts
Synovial ﬁbroblasts (1 × 105 cells) suspended in 200μLo f
RPMI 1640 medium supplemented with 1% FBS, 0.9% BSA
and antibiotics were precultured for 24 hours at 37◦C. Af-
ter the preculture, the culture medium was changed to RPMI
1640 medium supplemented with 10% FBS and cells were
cultured in the presence or absence of compounds for 48
hours at 37◦C followed by 24 hours culture in the pres-
ence of 1.25μCi/mL of [methyl-3H] thymidine. In the case
of methotrexate and leﬂunomide, 1.25μCi/mL of [6-3H] de-
oxyuridine was also used instead of [methyl-3H] thymidine
[21, 22]. The incorporation of [3H] thymidine or [6-3H] de-
oxyuridine was counted by a liquid scintillation counter.
2.11. Statisticalanalyses
The Student’s t test or Aspin-Welch test following an F-test
was used for analysis of diﬀerences between the two groups.
Multiple comparisons among treatment groups were per-
formed by 1-way ANOVA followed by the Dunnett test or
Kruskal-Wallis followed by the Steel test. P values less than
.05 were considered to be statistically signiﬁcant.
3. RESULTS
3.1. Timecourseanalysisofthemurinepannusmodel
The granulomas collected on the indicated days were
chopped into pieces in culture medium. Cytokine concen-
trations and anti-mBSA speciﬁc IgG1 and IgM antibody titer
in the supernatants were measured after 24-hour incuba-
tion without any manipulation to extract cytokines from
the granulomatous tissues (Figure 1). The concentration of
IL-1β peaked on day 10 and then gradually decreased in
the mBSA-treated group (Figure 1(a)). TNF-α and IL-6 were
both released on day 1, transiently decreased on day 3, and
were constantly released until day 30 (Figures 1(b), 1(c)). IL-
12 release peaked on day 6, while IFN-γ was slightly delayed
andpeak edonda y10(Figure 1(d)anddatanotshown).IL-4
andIL-10weresigniﬁcantlyincreasedonlyonday1(datanot
shown). Anti-mBSA speciﬁc IgG1 antibody concentration
wassigniﬁcantlyincreasedfromday6andsustaineduntilday
22 (data not shown). Anti-mBSA speciﬁc IgM antibody con-
centration was signiﬁcantly increased from day 1 and peaked
on day 15 (data not shown). Myeloperoxidase (MPO) activ-
ity, a marker enzyme for neutrophil inﬁltration in the mix-
ture of the culture medium and the granuloma, was con-
stantly high in the mBSA-treated group (Figure 1(e)). Hy-
droxyproline content, a marker of ﬁbrosis, increased with
t i m ea n dp e a k e do nd a y1 5i nt h eg r a n u l o m a( Figure 1(f)).
3.2. Evaluationofantirheumaticdrugs
andPDE4inhibitors
Drugs were orally administered for 10 days from the day
of the implantation of mBSA-soaked ﬁlter in the back of
the mice. IL-1β production from the granuloma was sup-
pressed by both PDE4 inhibitors, KF66490 and SB207499,
leﬂunomide, and prednisolone, but not by methotrexate4 Mediators of Inﬂammation
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Figure 1: Time course of cytokine productions, myeloperoxidase (MPO) activity, and hydroxyproline content in the mBSA-induced granu-
lomatous tissue. Mice sensitized with mBSA were challenged by subcutaneous implantation of a membrane ﬁlter soaked in mBSA solution
in the back of the mice on day 0. Granuloma was collected on the indicated days and cultured in vitro for 24hr. Cytokines were measured in
the supernatants. MPO activity and hydroxyproline content were measured in a mixture of the culture medium and the granuloma. IL-1β
(a), TNF-α (b), IL-6 (c), IL-12 (d), MPO activity (e), and hydroxyproline content (f). Results are shown as the mean ± SE of 4 to 6 mice.
#: P<. 05, ##: P<. 01, ###: P<. 001 (The Student’s t test), ∗P<. 05, ∗∗P<. 01, ∗∗∗P<. 001 (Aspin-Welch test). Representative data from
three independent experiments are shown.
(Figure 2(a)). TNF-α production was suppressed by all drugs
(Figure 2(b)). IL-6 production was suppressed by all drugs
except KF66490 (Figure 2(c)). IL-12 production was sup-
pressed by both PDE4 inhibitors and prednisolone and par-
tially by leﬂunomide but not by methotrexate (Figure 2(d)).
Increase in MPO activity was suppressed by all drugs ex-
cept for methotrexate (Figure 2(e)). Increase in hydroxypro-
line content was suppressed by all drugs except methotrexate
(Figure 2(f)). Summary of the data in this study are shown
in Tables 1 and 2. PDE4 inhibitors showed a wide range of
eﬀects in this model. PDE4 inhibitors suppressed anti-mBSA
speciﬁc IgG1 antibody production, but not anti-mBSA spe-
ciﬁc IgM antibody production. Leﬂunomide and methotrex-
ate strongly suppressed both IgG1 and IgM antibody pro-
duction. Nonsteroidal anti-inﬂammatory drugs (NSAIDS),
diclofenac signiﬁcantly increased the TNF-α and IL-12 pro-
duction. None of the drugs aﬀected the body weight increase
except prednisolone, which signiﬁcantly suppressed it both
at 10 and 30mg/kg (data not shown).
3.3. Cytokineproductionfromthioglycolate-elicited
peritonealmacrophages
To evaluate the eﬀects of PDE4 inhibitors on proin-
ﬂammatory cytokine production, LPS-stimulated TNF-α
and IL-12 production from thioglycolate-elicited peritoneal
macrophages were conducted in vitro. Both PDE4 inhibitors
suppressed LPS-stimulated TNF-α and IL-12 production
with IC50 values of 0.88 and 4.2μmol/L (KF66490), and 0.12
and 0.52μmol/L (SB207499), respectively (Table 3).
3.4. Proliferationofratsynovialﬁbroblasts
To evaluate the antiproliferative activity of PDE4 inhibitors
and antirheumatic drugs on ﬁbroblasts, the proliferation
of rat synovial ﬁbroblasts was conducted. KF66490 and
SB207499 inhibited serum-stimulated proliferation of rat
synovialﬁbroblastswithanIC50 valuesof9.2and3.1μmol/L,
respectively (Table 4). Leﬂunomide did not inhibit it even atKatsuya Kobayashi et al. 5
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Figure 2: Eﬀects of antirheumatic drugs and a PDE4 inhibitor on the mBSA-induced granuloma. Drugs were orally administered once a
day from day 0 to 10. On day 11, the granuloma was collected and cultured for 24h at 37◦C. Cytokine concentrations in the supernatants
and MPO activity and hydroxyproline content in the mixture of the culture medium and the granuloma were measured. PDE4 inhibitors,
KF66490(3,10,30mg/kg)andSB207499(3,10,30mg/kg),leﬂunomide(3,10,30mg/kg),prednisolone(3,10,30mg/kg),andmethotrexate
(3, 10mg/kg) were orally administered. IL-1β (a), TNF-α (b), IL-6 (c), IL-12 (d), MPO activity (e), and hydroxyproline content (f). Results
are shown as the mean ± SE of 6 to 10 mice. ###: P<. 001 (The Student’s t test), ∗∗P<. 01, ∗∗∗P<. 001 (Aspin-Welch test), +: P<. 05,
++: P<. 01, +++: P<. 001 (Dunnett test), §: P<. 05, §§: P<. 01, §§§: P<. 001 (Steel test). Representative data from three independent
experiments are shown.
100μmol/L.Prednisolone andmethotrexateinhibited itwith
IC50 values of 0.070 and 0.013μmol/L, respectively.
4. DISCUSSION
We have shown that this pannus model makes it much
easier to determine a variety of cytokines produced in the
granuloma than the previous methods which needs many
steps to extract cytokines from tissue, and the type of cy-
tokines is very similar to that reported to be increased in the
pannus in the patients with RA. Antirheumatic drugs sup-
pressed these cytokine productions and hydroxyproline con-
tents. These results suggest that this model could be a rele-
vant model for evaluation of pannus formation in patients
with RA. Both PDE4 inhibitors, KF66490 and SB207499,
showed an eﬀect comparable to those of antirheumatic
drugs in this model; and also, PDE4 inhibitors inhibited
lipopolysaccharide-induced TNF-α and IL-12 production
from thioglycolate-induced murine peritoneal macrophages
and the proliferation of rat synovial ﬁbroblasts. Therefore,
PDE4 inhibitors could have therapeutic eﬀects on pannus
formation in RA by inhibition of cytokine production by
macrophages and synovial ﬁbroblast proliferation.
There was no report on the measurement of cytokines in
delayed-type hypersensitivity granuloma. We compared cy-
tokine concentrations between in-tissue homogenate sam-
ples and in-culture supernatants of the granuloma. However,
amarkedvariabilityofcytokineconcentrationswasobserved
in the case of using homogenate samples (data not shown).
The new method showed that the variation was relatively
small and could be useful for the measurment of cytokine
productions from granulomatous tissues.
A broad array of macrophages and ﬁbroblast cytokines,
including TNF-α, IL-1, IL-6, and IL-12 are produced by the6 Mediators of Inﬂammation
Table 1: Summary of cytokine productions.
Drug Dose (mg/kg) TNF-α IL-1β IL-6 IL-12
(% inhibition)
KF66490
35 0 ∗∗ 33 −83 5 ∗∗
10 61∗∗ 60∗ −41∗ 40∗∗
30 55∗∗ 80∗ 30 59∗∗∗
SB207499
34 1 ∗ 39 14 25
10 56∗∗ 65∗∗ 75 1 ∗∗∗
30 72∗∗∗ 86∗∗∗ 47∗ 72∗∗∗
Leﬂunomide
36 7 ∗∗ 29 9 −4
10 72∗∗ 48∗ 95 5 ∗
30 111∗∗∗ 71∗∗ 44∗∗ 43
Prednisolone
32 7 8 5 ∗ 59∗ 77∗
10 86∗∗∗ 60 65 87∗
30 107∗∗∗ 102∗∗ 93∗ 103∗∗
Methotrexate 36 3 −68 41∗ −17
10 83∗∗ 37 53∗∗ 10
Diclofenac 1 −68∗ −42 6 −37
3 −77∗ −95 1 ∗ −92∗
∗P<. 05, ∗∗P<. 01, ∗∗∗P<. 001. Representative data from two or three independent experiments are shown.
Table 2: Summary of MPO activity, hydroxyproline content, anti-mBSA IgG1, and anti-mBSA IgM antibody production.
Drug Dose (mg/kg) MPO Hydroxyproline Anti-mBSA IgG1antibody Anti-mBSA IgM antibody
(% inhibition)
KF66490
32 25 8 ∗ 34 9
10 61∗ 37 39 33
30 67∗ 75∗∗ 79∗ 34
SB207499
35 0 ∗ 61∗∗ 38 11
10 51∗ 47∗ 81∗ 39
30 83∗∗∗ 78∗∗∗ 61 34
Leﬂunomide
3 −20 46∗ 42 34
10 36 62∗∗ 95∗ 86∗
30 80∗∗ 72∗∗∗ 104∗ 100∗
Prednisolone
36 0 7 9 ∗∗ 68∗ 45
10 9 81∗∗ 75∗ 55
30 99∗ 100∗∗∗ 90∗ 67
Methotrexate 3 −22 9 47 40
10 52 25 87∗∗ 91∗
Diclofenac 1 −29 27 17 −86
3 −66 −18 20 −120
∗P<. 05, ∗∗P<. 01, ∗∗∗P<. 001. Representative data from two or three independent experiments are shown.
rheumatoid synovium in the pannus [23–25]. TNF-α,I L -
1β, and IL-6 have been reported to play a pivotal role in the
pathogenicmechanismsofRA[26–28].Inthisstudy,chronic
production of TNF-α,I L - 1 β, IL-6, and IL-12 was observed.
These observations suggest that this pannus model is useful
for evaluating the eﬀects of drugs on the production of cy-
tokines involved in the pathogenic mechanisms of RA. PDE4
inhibitors suppressed these all cytokine production in vivo
and TNF-α and IL-12 production in vitro. These results sug-
gest that PDE4 inhibitors directly suppress the production of
TNF-α and IL-12, and indirectly suppress the production of
IL-1β and IL-6 which are possibly induced by TNF-α stim-
ulation. Because it has been reported that TNF-α transgenic
mice develop arthritis with enhanced production of TNF-α,
IL-1, and IL-6 [29], which means TNF-α is the major dom-
inant regulator of IL-1β and IL-6 [30]. Additional explana-
tion of antipannus forming eﬀects of PDE4 inhibitors is the
inhibition of ﬁbroblast proliferation. The maximum plasma
concentrationofSB207499wasabout19μmol/Latthemaxi-
mum dose used in this study (30mg/kg p.o.) [31]. Therefore,
the inhibition of ﬁbroblast proliferation is considered to be
involved in antipannus forming eﬀects of PDE4 inhibitors.Katsuya Kobayashi et al. 7
Table 3: IC50 values of KF66490 and SB207499 on LPS-
induced cytokine production from thioglycolate-elicited peritoneal
macrophages.
TNF-α IL-12
(IC50: μmol/L)
KF66490 0.88 4.2
SB207499 0.12 0.52
Thioglycolate-induced adherent peritoneal cells were stimulated with
1μg/mLofLPSinthepresenceorabsenceofcompoundsfor6.5h(forTNF-
α) or 24h (for IL-12) at 37◦C. After the incubation, cytokines were mea-
sured by ELISA kits in the supernatants. Data are mean value of two or three
independent experiments.
Table 4: IC50 values of various drugs on serum-induced prolifera-
tion of rat synovial ﬁbroblasts.
Drug IC50 (μmol/L)
KF66490 9.2
SB207499 3.1
Leﬂunomide >100
Prednisolone 0.070
Methotrexate 0.013
Ratsynovialﬁbroblastswerepre-culturedinculturemediumsupplemented
with 1% FBS for 24h at 37◦C. After the preculture, cells were stimulated by
10% FBS in the presence or absence of compounds for 48h at 37◦Cf o ll o w ed
by 24h culture in the presence of 1.25μCi/mL of [methyl-3H] thymidine
or [6-3H] deoxyuridine. The incorporation of [3H] thymidine or [6-3H]
deoxyuridine was counted by a liquid scintillation counter. Data are mean
value of three or four separate determinations.
Some autoantibody levels in the synovial ﬂuid are specif-
ically related to the pathogenesis of RA [32, 33]. PDE4 in-
hibitors suppressed IgG1 but not IgM production in the pan-
nus supernatants. This ﬁnding conﬂicts with previous re-
ports that PDE4 inhibitors inhibit IgG1 or IgG2a antibody
production in vivo [34, 35], but they did not measure the
antibody levels in the inﬂammatory sites. These results sug-
gest that PDE4 inhibitors inhibit antibody production in the
inﬂammatory sites. It is not known exactly why PDE4 in-
hibitors suppressed the IgG1 production; but in our model,
IL-4 production on day 1 was completely inhibited by both
PDE4 inhibitors (85 or 83% inhibition at 10 or 30mg/kg of
KF66490 and 53 or 103% inhibition at 10 or 30mg/kg of
SB207499). IL-4 is known to promote the proliferation and
diﬀerentiation of activated B-cells. Therefore, the suppres-
sion of IL-4 production by PDE4 inhibitors may have had
some inhibitory eﬀects on B cells.
It has been reported that PDE4 inhibitors suppress both
Th1a n dT h2 cytokine production from stimulated T cells
in vitro [36, 37]. However, the inhibition is partial. There-
fore, we believe that the suppression of T cell function is less
involved in antipannus eﬀects of PDE4 inhibitors because
no obvious inhibition of IFN-γ production was observed
in our model (data not shown); and also, we did not ﬁnd
any eﬀect on IFN-γ and IL-6 production from concanavalin.
A stimulated murine splenic T cells up to 10μmol/L (data
not shown). Interestingly, it has been reported that den-
dritic cells exposed to PDE4 inhibitors during maturation
reduce the development of IFN-γ-expressing eﬀector T cells
[38]. Therefore, PDE4 inhibitors seem to aﬀect the devel-
opment of Th1 cells in vitro; but as mentioned above, IL-
4 production was completely inhibited by PDE4 inhibitors
in our model. The suppression of IL-4 production by PDE4
inhibitors might have had an impact on Th1/Th2 balance.
Taken together, although PDE4 inhibitors preferentially di-
minish Th1 responses, some eﬀects of PDE4 inhibitors on
Th2 responses [36, 37] might complicate the in vivo re-
sponses. Consequently, we think the eﬀects of PDE4 in-
hibitors on in vivo Th1/Th2 responses depend on the type
of inﬂammation.
Recently, IL-17-producing T cells have been classiﬁed
as a new eﬀector T-cell subset, termed Th17, which is dis-
tinct from Th1, Th2, and Treg subsets. It is very interest-
ing to examine whether PDE4 inhibitors suppresses the IL-
23 or transforming growth factor (TGF-β) production from
macrophages. IL-23, IL-6, and TGF-β promote the diﬀeren-
tiation of Th17 cells, which are considered to act as the key
eﬀector-cell subset in inﬂammatory arthritis, at least in ro-
dents [39].
In conclusion, this study provides a unique murine
modeltoeasilyevaluatetheeﬀectsofthedrugsontheforma-
tion of the granuloma and cytokine production in a granu-
loma. PDE4 inhibitors showed an eﬀect comparable to those
of antirheumatic drugs in this model. The suppression of
TNF-α and IL-12 production and the inhibition of ﬁbroblast
proliferationwereconsideredtocontributetotheantipannus
forming eﬀects of PDE4 inhibitors.
ACKNOWLEDGMENTS
The authors would like to thank to Ms. Eri Okita for their
expert technical assistance and Mr. Koji Yanagawa for syn-
thesis of compounds. They are also grateful to Dr. Mark W
Lethbridge for kind discussion
REFERENCES
[1] D.E.Trentham,A.S.Townes,andA.H.Kang,“Autoimmunity
totypeIIcollagen:anexperimentalmodelofarthritis,”Journal
of Experimental Medicine, vol. 146, no. 3, pp. 857–868, 1977.
[2] K. D. Rainsford, “Adjuvant polyarthritis in rats: is this a sat-
isfactory model for screening anti-arthritic drugs?” Agents &
Actions, vol. 12, no. 4, pp. 452–458, 1982.
[3] K. Magari, S. Miyata, Y. Ohkubo, and S. Mutoh, “Inﬂamma-
tory cytokine levels in paw tissues during development of rat
collagen-induced arthritis: eﬀect of FK506, an inhibitor of T
cell activation,” Inﬂammation Research, vol. 53, no. 9, pp. 469–
474, 2004.
[4] G. Engelhardt, D. Homma, K. Schlegel, R. Utzmann, and
C. Schnitzler, “Anti-inﬂammatory, analgesic, antipyretic and
related properties of meloxicam, a new non-steroidal anti-
inﬂammatory agent with favourable gastrointestinal toler-
ance,” Inﬂammation Research, vol. 44, no. 10, pp. 423–433,
1995.
[5] C. Vingsbo, P. Sahlstrand, J. G. Brun, R. Jonsson, T. Saxne,
and R. Holmdahl, “Pristane-induced arthritis in rats: a new
model for rheumatoid arthritis with a chronic disease course
inﬂuenced by both major histocompatibility complex and8 Mediators of Inﬂammation
non-major histocompatibility complex genes,” American Jour-
nal of Pathology, vol. 149, no. 5, pp. 1675–1683, 1996.
[6] C. J. Dunn, A. J. Gibbons, and S. K. Miller, “Development of a
delayed-type hypersensitivity granuloma model in the mouse
for the study of chronic immune-mediated inﬂammatory dis-
ease,” Agents & Actions, vol. 27, no. 3-4, pp. 365–368, 1989.
[7] C. J. Dunn, L. A. Galinet, A. J. Gibbons, and S. K. Shields,
“Murine delayed-type hypersensitivity granuloma: an im-
proved model for the identiﬁcation and evaluation of diﬀer-
ent classes of anti-arthritic drugs,” International Journal of Im-
munopharmacology, vol. 12, no. 8, pp. 899–904, 1990.
[8] B. S¨ arnstrand, A.-H. Jansson, G. Matuseviciene, A. Scheynius,
S. Pierrou, and H. Bergstrand, “N,N
 -diacetyl-L-cystine—the
disulﬁde dimer of N-acetylcysteine—is a potent modulator of
contact sensitivity/delayed type hypersensitivity reactions in
rodents,”JournalofPharmacologyandExperimentalTherapeu-
tics, vol. 288, no. 3, pp. 1174–1184, 1999.
[9] W. B¨ aumer, J. Hoppmann, C. Rundfeldt, and M. Kietzmann,
“Highly selective phosphodiesterase 4 inhibitors for the treat-
ment of allergic skin diseases and psoriasis,” Inﬂammation &
Allergy - Drug Targets, vol. 6, no. 1, pp. 17–26, 2007.
[10] L. Sekut, D. Yarnall, S. A. Stimpson, et al., “Anti-inﬂammatory
activity of phosphodiesterase (PDE)-IV inhibitors in acute
andchronicmodelsofinﬂammation,”Clinical&Experimental
Immunology, vol. 100, no. 1, pp. 126–132, 1995.
[11] J. N. Francischi, C. M. Yokoro, S. Poole, W. L. Tafuri, F. Q.
Cunha, and M. M. Teixeira, “Anti-inﬂammatory and anal-
gesic eﬀects of the phosphodiesterase 4 inhibitor rolipram in
a rat model of arthritis,” European Journal of Pharmacology,
vol. 399, no. 2-3, pp. 243–249, 2000.
[12] L. Wollin, D. S. Bundschuh, A. Wohlsen, D. Marx, and R.
Beume, “Inhibition of airway hyperresponsiveness and pul-
monary inﬂammation by roﬂumilast and other PDE4 in-
hibitors,” Pulmonary Pharmacology & Therapeutics, vol. 19,
no. 5, pp. 343–352, 2006.
[13] A. Kanehiro, T. Ikemura, M. J. M¨ akel¨ a, et al., “Inhibition
of phosphodiesterase 4 attenuates airway hyperresponsiveness
and airway inﬂammation in a model of secondary allergen
challenge,” American Journal of Respiratory and Critical Care
Medicine, vol. 163, no. 1, pp. 173–184, 2001.
[ 1 4 ]F .J .J o h n s o n ,L .J .R e y n o l d s ,a n dT .J .T o w a r d ,“ E l a s t o l y t i ca c -
tivity and alveolar epithelial type-1 cell damage after chronic
LPS inhalation: eﬀects of dexamethasone and rolipram,” Toxi-
cology and Applied Pharmacology, vol. 207, no. 3, pp. 257–265,
2005.
[15] S. E. Ross, R. O. Williams, L. J. Mason, et al., “Suppression of
TNF-α expression, inhibition of Th1 activity, and ameliora-
tion of collagen-induced arthritis by rolipram,” Journal of Im-
munology, vol. 159, no. 12, pp. 6253–6259, 1997.
[16] Z. Huang and J. A. Mancini, “Phosphodiesterase 4 inhibitors
for the treatment of asthma and COPD,” Current Medicinal
Chemistry, vol. 13, no. 27, pp. 3253–3562, 2006.
[17] N. Cooper, M. M. Teixeira, J. Warneck, et al., “A compari-
son of the inhibitory activity of PDE4 inhibitors on leuko-
cyte PDE4 activity in vitro and eosinophil traﬃcking in vivo,”
BritishJournalofPharmacology,vol.126,no.8,pp.1863–1871,
1999.
[18] P. L. van Lent, K. Nabbe, A. B. Blom, et al., “Role of activa-
tory FcγRI and FcγRIII and inhibitory FcγRII in inﬂamma-
tion and cartilage destruction during experimental antigen-
induced arthritis,” American Journal of Pathology, vol. 159,
no. 6, pp. 2309–2320, 2001.
[19] C. Romay, N. Led´ on, and R. Gonz´ alez, “Further studies on
anti-inﬂammatory activity of phycocyanin in some animal
models of inﬂammation,” Inﬂammation Research, vol. 47,
no. 8, pp. 334–338, 1998.
[20] C. Jakubzick, E. S. Choi, B. H. Joshi, et al., “Therapeutic atten-
uation of pulmonary ﬁbrosis via targeting of IL-4- and IL-13-
responsive cells,” Journal of Immunology, vol. 171, no. 5, pp.
2684–2693, 2003.
[21] F.A.Meyer,I.Yaron,V.Mashiah,andM.Yaron,“Methotrexate
inhibits proliferation but not interleukin 1 stimulated secre-
tory activities of cultured human synovial ﬁbroblasts,” Journal
of Rheumatology, vol. 20, no. 2, pp. 238–242, 1993.
[22] N. J. Olsen and L. M. Murray, “Antiproliferative eﬀects of
methotrexate on peripheral blood mononuclear cells,” Arthri-
tis & Rheumatism, vol. 32, no. 4, pp. 378–385, 1989.
[23] G. S. Firestein, “Evolving concepts of rheumatoid arthritis,”
Nature, vol. 423, no. 6937, pp. 356–361, 2003.
[24] A. Bucht, P. Larsson, L. Weisbrot, et al., “Expression of
interferon-gamma (IFN-γ), IL-10, IL-12 and transforming
growthfactor-beta(TGF-β)mRNAinsynovialﬂuidcellsfrom
patients in the early and late phases of rheumatoid arthritis
(RA),” Clinical & Experimental Immunology, vol. 103, no. 3,
pp. 357–367, 1996.
[25] Y. Morita, M. Yamamura, K. Nishida, et al., “Expression of
interleukin-12 in synovial tissue from patients with rheuma-
toid arthritis,” Arthritis & Rheumatism, vol. 41, no. 2, pp. 306–
314, 1998.
[26] F. Puppo, G. Murdaca, M. Ghio, and F. Indiveri, “Emerging
biologic drugs for the treatment of rheumatoid arthritis,” Au-
toimmunity Reviews, vol. 4, no. 8, pp. 537–541, 2005.
[27] E. H. Choy, D. A. Isenberg, T. Garrood, et al., “Therapeu-
tic beneﬁt of blocking interleukin-6 activity with an anti-
interleukin-6 receptor monoclonal antibody in rheumatoid
arthritis: a randomized, double-blind, placebo-controlled,
dose-escalation trial,” Arthritis & Rheumatism, vol. 46, no. 12,
pp. 3143–3150, 2002.
[28] N. Nishimoto, K. Yoshizaki, N. Miyasaka, et al., “Treatment
of rheumatoid arthritis with humanized anti-interleukin-
6 receptor antibody: a multicenter, double-blind, placebo-
controlled trial,” Arthritis & Rheumatism,v o l .5 0 ,n o .6 ,p p .
1761–1769, 2004.
[29] V. Kouskoﬀ,A . - S .K o r g a n o w ,V .D u c h a t e l l e ,C .D e g o t t ,C .
Benoist, and D. Mathis, “Organ-speciﬁc disease provoked by
systemic autoimmunity,” Cell, vol. 87, no. 5, pp. 811–822,
1996.
[30] M. Feldmann, F. M. Brennan, and R. N. Maini, “Role of cy-
tokines in rheumatoid arthritis,” Annual Review of Immunol-
ogy, vol. 14, pp. 397–440, 1996.
[31] D. E. Griswold, E. F. Webb, A. M. Badger, et al., “SB 207499
(Ariﬂo), a second generation phosphodiesterase 4 inhibitor,
reduces tumor necrosis factor α and interleukin-4 production
in vivo,” Journal of Pharmacology and Experimental Therapeu-
tics, vol. 287, no. 2, pp. 705–711, 1998.
[32] H.-S. Cha, T. J. Kim, J.-Y. Kim, et al., “Autoantibodies to
glucose-6-phosphate isomerase are elevated in the synovial
ﬂuid of rheumatoid arthritis patients,” Scandinavian Journal
of Rheumatology, vol. 33, no. 3, pp. 179–184, 2004.
[33] M.Schaller ,W .Stohl,V .Benoit,S.-M.T an,L.Johansen,andH.
J.Ditzel,“Patientswithinﬂammatoryarthriticdiseasesharbor
elevated serum and synovial ﬂuid levels of free and immune-
complexed glucose-6-phosphate isomerase (G6PI),” Biochem-
ical and Biophysical Research Communications, vol. 349, no. 2,
pp. 838–845, 2006.
[34] K. Yamaki, X. Li, H. Uchida, et al., “Eﬀects of the phospho-
diesterase IV inhibitor rolipram on Th1 and Th2 immuneKatsuya Kobayashi et al. 9
responses in mice,” Journal of Pharmacy and Pharmacology,
vol. 56, no. 7, pp. 877–882, 2004.
[35] K. Yamaki, X. Li, M. A. Hossain, et al., “Diﬀerence in pre-
ventive eﬀects between the phosphodiesterase IV inhibitor
rolipram and anti-arthritic drugs on antigen-induced arthri-
tis in mice,” Immunological Investigations,v o l .3 6 ,n o .2 ,p p .
131–145, 2007.
[36] A. Hatzelmann and C. Schudt, “Anti-inﬂammatory and im-
munomodulatory potential of the novel PDE4 inhibitor rof-
lumilast in vitro,” Journal of Pharmacology and Experimental
Therapeutics, vol. 297, no. 1, pp. 267–279, 2001.
[37] D. Claveau, S. L. Chen, S. O’Keefe, et al., “Preferential inhibi-
tion of T helper 1, but not T helper 2, cytokines in vitro by
L-826,141 [4-{2-(3,4-bisdiﬂuromethoxyphenyl)-2-{4-(1,1,1,
3,3,3-hexaﬂuoro-2-hydroxypropan-2-yl)-phenyl]-ethyl}-
3-methylpyridine-1-oxide], a Potent and Selective Phos-
phodiesterase 4 Inhibitor,” Journal of Pharmacology and
Experimental Therapeutics, vol. 310, no. 2, pp. 752–760, 2004.
[38] H. C. Heystek, A.-C. Thierry, P. Soulard, and C. Moulon,
“Phosphodiesterase 4 inhibitors reduce human dendritic cell
inﬂammatorycytokine productionand Th1-polarizing capac-
ity,” International Immunology, vol. 15, no. 7, pp. 827–835,
2003.
[39] I. B. McInnes and G. Schett, “Cytokines in the pathogenesis
of rheumatoid arthritis,” Nature Reviews Immunology, vol. 7,
no. 6, pp. 429–442, 2007.